Analysts Set Sensus Healthcare, Inc. (NASDAQ:SRTS) Target Price at $8.00

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have earned an average recommendation of “Hold” from the five brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $8.00.

SRTS has been the subject of several research reports. Wall Street Zen upgraded shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Sensus Healthcare from a “strong sell” rating to a “hold” rating in a report on Wednesday, October 22nd.

Insider Activity

In other news, CEO Joseph C. Sardano purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, November 18th. The stock was acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the purchase, the chief executive officer owned 1,200,293 shares in the company, valued at $4,837,180.79. This represents a 2.13% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Sachetta bought 7,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $3.93 per share, with a total value of $27,510.00. Following the completion of the transaction, the director directly owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. This represents a 5.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 36,500 shares of company stock valued at $147,570. 8.90% of the stock is owned by corporate insiders.

Institutional Trading of Sensus Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the company. Opes Wealth Management LLC acquired a new stake in Sensus Healthcare during the third quarter worth about $50,000. Vise Technologies Inc. bought a new stake in shares of Sensus Healthcare in the 2nd quarter valued at approximately $52,000. Mindset Wealth Management LLC raised its stake in Sensus Healthcare by 28.1% during the third quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after acquiring an additional 11,000 shares in the last quarter. Evernest Financial Advisors LLC bought a new position in Sensus Healthcare during the 2nd quarter valued at about $255,000. Finally, Sachetta LLC boosted its holdings in shares of Sensus Healthcare by 8.0% in the 3rd quarter. Sachetta LLC now owns 139,008 shares of the company’s stock worth $436,000 after acquiring an additional 10,333 shares in the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Stock Up 4.1%

Shares of Sensus Healthcare stock opened at $5.04 on Thursday. Sensus Healthcare has a fifty-two week low of $3.03 and a fifty-two week high of $6.35. The firm has a market cap of $82.76 million, a P/E ratio of -26.53 and a beta of 1.21. The business has a 50-day moving average price of $4.40 and a 200 day moving average price of $3.94.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 5.67% and a negative net margin of 8.44%.The firm had revenue of $6.88 million for the quarter, compared to analysts’ expectations of $6.31 million. As a group, equities research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current year.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.